Clinical and immunologic effects of a PRIMATIZED® anti-CD4 monoclonal antibody in active rheumatoid arthritis: Results of a phase I, single dose, dose escalating trial

Journal of Rheumatology

Volumn 25, Issue 7, 1998, Pages 1257-1262

  Yocum, David E ^a,b   Solinger, Alan M ^a   Tesser, John ^a   Gluck, Oscar ^a   Cornett, Michelle ^a   O'Sullivan, Frank ^a   Nordensson, Kathy ^a   Dallaire, Brian ^a   Shen, C David ^a   Lipani, John ^a,c  

^a UNIVERSITY OF ARIZONA   (United States)

^b Arizona Arthritis Center   (United States)

^c AHSC ^*

Author keywords

Anti CD4; Monoclonal antibody; Rheumatoid arthritis; Treatment

Indexed keywords

OKT 4;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECT; DRUG SAFETY; FEMALE; HUMAN; IMMUNOMODULATION; MALE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; T LYMPHOCYTE;

ADULT; AGED; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, CD4; ARTHRITIS, RHEUMATOID; CD4 LYMPHOCYTE COUNT; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; HUMANS; MACACA; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 0031862925     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Decker JL, Malone DG, Haraoui B, et al. Rheumatoid arthritis: Evolving concepts of pathogenesis and treatment. Ann Intern Med 1984;101:810-24.
2. Amor B, Herson D, Cherot A, et al. Follow-up study of patients with rheumatoid arthritis over a period of more than 10 years (1966-1978): Analysis of disease progression and treatment in 100 cases. Ann Med Intern 1981;132:168-73.
3. Pincus T, Callahan LF. Taking mortality in rheumatoid arthritis seriously: Predictive markers, socioeconomic status and comorbidity. J Rheumatol 1986;13:841-5.
4. Alpert SD, Koide J, Takada S, et al. T cell regulatory disturbances in rheumatic diseases. Rheum Dis Clin North Am 1987;13:431-55.
5. Brahn E, Helfgott SM, Bell JA, et al. Total lymphoid irradiation therapy in refractory rheumatoid arthritis: Fifteen-to-forty-month follow-up. Arthritis Rheum 1984;27:481-8.
6. Strand V, Lipsky P, Cannon G, et al. Effects of administration of an anti-CD5 plus immunoconjugate in rheumatoid arthritis: results of two phase II studies. Arthritis Rheum 1993;36:620-30.
7. Isaacs JD, Watts RA, Hazleman BL, et al. Humanized monoclonal therapy for rheumatoid arthritis. Lancet 1992;340:748-52.
8. Wahl SM, Wilder RL, Katona IM. Leukapheresis in rheumatoid arthritis: Association of clinical improvement with reversal of anergy. Arthritis Rheum 1983;26:1076-84.
9. Ranges GE, Sriram S, Cooper SM. Prevention of collagen induced arthritis by in vitro treatment with anti-CD4. J Exp Med 1985;162:1105-10.
10. Wofsy D, Seaman WE. Successful treatment of autoimmunity in NZB/NZW F, mice with monoclonal antibody to L3T3. J Exp Med 1985;161:378-91.
11. Wendung D, Racadot E, Morel-Fourrier B, Wijdenes J. Treatment of rheumatoid arthritis with anti-CD4 monoclonal antibody: open study of 25 patients with the B-F5 clone. Clin Rheum 1992;11:542-7.
12. Horneff G, Burmeister GR, Emmrich F, Kalden J Jr. Treatment of rheumatoid arthritis with an anti-CD4 monoclonal antibody. Arthritis Rheum 1991;34:129-40.
13. Moreland LW, Bucy RP, Tilden A, et al. Use of a chimeric monoclonal anti-CD4 antibody in patients with refractory rheumatoid arthritis. Arthritis Rheum 1993; 36:307-18.
14. Choy EHS, Chikanza IC, Kingsley GH, Corrigal V, Panayi G. Treatment of rheumatoid arthritis with single dose or weekly pulses of chimeric anti-CD4 monoclonal antibody. Scand J Immunol 1992;36:291-8.
15. Moreland LW, Pratt PW, Bucy RP, Jackson BS, Feldman JW, Koopman WJ. Treatment of Refractory Rheumatoid arthritis with a chimeric anti-CD monoclonal antibody: Longterm followup of CD4+ T cells. Arthritis Rheum 1994;37:834-8.
16. Matteson EL, Yocum DE, St. Clair EW, et al. Treatment of refractory rheumatoid arthritis with humanized monoclonal antibody Campath 1H administered by daily subcutaneous injection. Arthritis Rheum 1995;38:1187-93.
17. Jendro MC, Ganten T, Matteson EL, Weyand CM, Goronzy JJ. Emergence of oligoclonal T cell populations following therapeutic T cell depletion in rheumatoid arthritis. Arthritis Rheum 1995;38:1242-51.
18. Moreland LW, Sewell KL, Trentham DE, et al. Interleukin 2 diphtheria fusion protein (DAB486 IL-2) in refractory rheumatoid arthritis in a double-blind, placebo-controlled study of CD4 monoclonal antibody therapy in early rheumatoid arthritis. Arthritis Rheum 1995;38:1177-86.
19. Vander Lubbe PA, Dijkmans BAC, Markusse HM, Nässander V, Breedveld FC. A randomized, double blind, placebo controlled study of CD4 monoclonal antibody therapy in early rheumatoid arthritis. Arthritis Rheum 1995;38:1097-106.
20. Weinblatt ME, Maddison PJ, Bulpitt KJ, et al. Campath-1H, a humanized monoclonal antibody, in refractory rheumatoid arthritis. Arthritis Rheum 1995;38:1589-94.
21. Moreland LW, Pratt PW, Mayes MD, et al. Double blind, placebo controlled multicenter trial using chimeric monoclonal anti-CD4 antibody, CM-T412, in rheumatoid arthritis patients receiving concomitant methotrexate. Arthritis Rheum 1995;38:1581-8.
22. Choy EHS, Pitzalis C, Cauli A, et al. Percentage of anti-CD4 monoclonal antibody coated lymphocytes in the rheumatoid joint is associated with clinical improvement: Implications for the development of immunotherapeutic dosing regimens. Arthritis Rheum 1996;39:52-6.
23. Olsen NJ, Brook RH, Cush JJ, et al. Study of anti-CD5 immuno conjugate in patients with rheumatoid arthritis. Arthritis Rheum 1996;39:1102-8.
24. 2 by intravenous administration of Campath-1H in patients with rheumatoid arthritis. J Rheumatol 1995;22:1816-9.
25. Isaacs JD, Manna VK, Rupson N, et al. Campath-1H in rheumatoid arthritis - an intravenous dose-ranging study. Brit J Rheumatology 1996;35:231-40.
26. Ropes MW, Bennett GA, Cobb S, Jacob R, Jessar RA. 1958 revision of diagnostic criteria for rheumatoid arthritis. Bull Rheum Dis 1958;9:175-6.
27. Newman R, Alberts J, Anderson D, et al. "Primatization" of recombinant antibodies for immunotherapy of human diseases: a macaque/human chimeric antibody against human CD4. Biotechnology 1992;10:1455-60.
28. Ritchie DM, Boyle JA, McInnes JM, et al. Clinical studies with an articular index for the assessment of joint tenderness in patients with rheumatoid arthritis. QJ Med 1968;37:393-406.
29. Halpern MD, Yocum DE. The paradoxical effects of diethyldithiocarbamate: Comparisons between New Zealand Black/White F1 hybrid and Balb/c mice. Clin Immunol Pathol 1991;58:69-79.
30. Yocum DE, Wilder RL, Daugherty S, Klippel JH, Pillemer S, Wahl S. Immunologic parameters of response in patients with rheumatoid arthritis treated with cyclosporin A. Arthritis Rheum 1990;33: 1310-6.
31. Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology preliminary criteria for improvement in rheumatoid arthritis trials. Arthritis Rheum 1995; 38:727-35.
32. Bartholomew M, Brett S, Barber K, Rossman C, Crowe S, Tite J. Functional analysis of the effects of a fully humanized anti-CD4 antibody on resting and activated human T cells. Immunology 1995;85:41-8.